573 related articles for article (PubMed ID: 27770808)
1. p14 expression differences in ovarian benign, borderline and malignant epithelial tumors.
Cabral VD; Cerski MR; Sa Brito IT; Kliemann LM
J Ovarian Res; 2016 Oct; 9(1):69. PubMed ID: 27770808
[TBL] [Abstract][Full Text] [Related]
2. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
3. Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms.
Giordano G; Azzoni C; D'Adda T; Rocco A; Gnetti L; Froio E; Merisio C; Melpignano M
Pathol Res Pract; 2008; 204(3):163-74. PubMed ID: 18180113
[TBL] [Abstract][Full Text] [Related]
4. Possible associations among expression of p14(ARF), p16(INK4a), p21(WAF1/CIP1), p27(KIP1), and p53 accumulation and the balance of apoptosis and cell proliferation in ovarian carcinomas.
Saegusa M; Machida B D; Okayasu I
Cancer; 2001 Sep; 92(5):1177-89. PubMed ID: 11571731
[TBL] [Abstract][Full Text] [Related]
5. Stromal p16 expression is significantly increased in malignant ovarian neoplasms.
Yoon N; Yoon G; Park CK; Kim HS
Oncotarget; 2016 Oct; 7(40):64665-64673. PubMed ID: 27572321
[TBL] [Abstract][Full Text] [Related]
6. Profiles of the 2 INK4a gene products, p16 and p14ARF, in human reference urothelium and bladder carcinomas, according to pRb and p53 protein status.
Le Frère-Belda MA; Gil Diez de Medina S; Daher A; Martin N; Albaud B; Heudes D; Abbou CC; Thiery JP; Zafrani ES; Radvanyi F; Chopin D
Hum Pathol; 2004 Jul; 35(7):817-24. PubMed ID: 15257544
[TBL] [Abstract][Full Text] [Related]
7. PTK7 protein is decreased in epithelial ovarian carcinomas with poor prognosis.
Wang H; Li G; Yin Y; Wang J; Wang H; Wei W; Guo Q; Ma H; Shi Q; Zhou X; Wang J
Int J Clin Exp Pathol; 2014; 7(11):7881-9. PubMed ID: 25550828
[TBL] [Abstract][Full Text] [Related]
8. Inverse expression of Cdk4 and p16 in epithelial ovarian tumors.
Sui L; Dong Y; Ohno M; Goto M; Inohara T; Sugimoto K; Tai Y; Hando T; Tokuda M
Gynecol Oncol; 2000 Nov; 79(2):230-7. PubMed ID: 11063650
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors.
Berchuck A; Kohler MF; Hopkins MP; Humphrey PA; Robboy SJ; Rodriguez GC; Soper JT; Clarke-Pearson DL; Bast RC
Gynecol Oncol; 1994 Feb; 52(2):232-6. PubMed ID: 7508877
[TBL] [Abstract][Full Text] [Related]
10. The immunohistochemical expression of p53 and Ki67 in ovarian epithelial borderline tumors. Correlation with clinicopathological factors.
Giurgea LN; Ungureanu C; Mihailovici MS
Rom J Morphol Embryol; 2012; 53(4):967-73. PubMed ID: 23303020
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of senescence markers p14(ARF) and p16(INK4a) in breast cancer is associated with an increased risk of disease recurrence and poor survival outcome.
Pare R; Shin JS; Lee CS
Histopathology; 2016 Sep; 69(3):479-91. PubMed ID: 26843058
[TBL] [Abstract][Full Text] [Related]
12. High frequency of p16 and p14 promoter hypermethylation and marked telomere instability in salivary gland tumors.
Nikolic N; Anicic B; Carkic J; Simonovic J; Toljic B; Tanic N; Tepavcevic Z; Vukadinovic M; Konstantinovic VS; Milasin J
Arch Oral Biol; 2015 Nov; 60(11):1662-6. PubMed ID: 26351750
[TBL] [Abstract][Full Text] [Related]
13. Loss of p16INK4A expression in low-grade ovarian serous carcinomas.
Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J
Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838
[TBL] [Abstract][Full Text] [Related]
14. The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma.
Khouja MH; Baekelandt M; Nesland JM; Holm R
Int J Gynecol Pathol; 2007 Oct; 26(4):418-25. PubMed ID: 17885492
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
16. P53, bcl-2, and nm23 expressions in serous ovarian tumors: correlation with the clinical and histopathological parameters.
Arik D; Kulaçoğlu S
Turk Patoloji Derg; 2011 Jan; 27(1):38-45. PubMed ID: 21469425
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors.
Zagorianakou N; Stefanou D; Makrydimas G; Zagorianakou P; Briasoulis E; Karavasilis V; Pavlidis N; Agnantis NJ
Histol Histopathol; 2006 Apr; 21(4):341-7. PubMed ID: 16437378
[TBL] [Abstract][Full Text] [Related]
18. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors].
Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848
[TBL] [Abstract][Full Text] [Related]
19. p16 overexpression: a potential early indicator of transformation in ovarian carcinoma.
Shigemasa K; Hu C; West CM; Clarke J; Parham GP; Parmley TH; Korourian S; Baker VV; O'Brien TJ
J Soc Gynecol Investig; 1997; 4(2):95-102. PubMed ID: 9101469
[TBL] [Abstract][Full Text] [Related]
20. The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.
Bar JK; Grelewski P; Noga L; Rabczyński J; Gryboś M; Jeleń M
Adv Clin Exp Med; 2012; 21(1):35-42. PubMed ID: 23214297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
